Daniel Bergemalm

Articles in journals

• Thunberg, J. , Grännö, O. , Bergemalm, D. , Eriksson, C. , Visuri, I. , Eberhardson, M. & Halfvarson, J. (2024). Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels.  Scandinavian Journal of Gastroenterology, 59 (2), 150-155. [BibTeX]
• Ling Lundström, M. , Peterson, C. , Hedin, C. R. H. , Bergemalm, D. , Lampinen, M. , Magnusson, M. K. , Keita, Å. V. , Kruse, R. & et al. (2024). Faecal biomarkers for diagnosis and prediction of disease course in treatment-naïve patients with IBD.  Alimentary Pharmacology and Therapeutics, 60 (6), 765-777. [BibTeX]
• Kalla, R. , Adams, A. T. , Nowak, J. K. , Bergemalm, D. , Vatn, S. , Ventham, N. T. , Kennedy, N. A. , Ricanek, P. & et al. (2023). Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic, and immune-inflammatory influences on the circulating methylome.  Journal of Crohn's & Colitis, 17 (2), 170-184. [BibTeX]
• Mahajna, H. , Verstockt, B. , Bergemalm, D. , Castiglione, F. , Rodríguez-Moranta, F. , Savarino, E. V. , Hoentjen, F. , Bessissow, T. & et al. (2023). Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series.  Journal of Crohn's & Colitis, 17 (5), 722-727. [BibTeX]
• Wallhuss, A. , Ottosson, J. , Cao, Y. , Andersson, E. , Bergemalm, D. , Eriksson, C. , Olén, O. , Szabo, E. & et al. (2023). Outcomes of bariatric surgery for patients with prevalent inflammatory bowel disease: A nationwide registry-based cohort study.  Surgery, 174 (2), 144-151. [BibTeX]
• Shubhakar, A. , Jansen, B. C. , Adams, A. T. , Reiding, K. R. , Ventham, N. T. , Kalla, R. , Bergemalm, D. , Urbanowicz, P. A. & et al. (2023). Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease.  Journal of Crohn's & Colitis, 17 (6), 919-932. [BibTeX]
• Eriksson, C. , Söderling, J. , Karlqvist, S. , Bröms, G. , Everhov, Å. H. , Bergemalm, D. , Ludvigsson, J. F. , Olén, O. & et al. (2023). Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.  Digestive Diseases and Sciences, 68 (7), 3119-3128. [BibTeX]
• Nowak, J. K. , Adams, A. T. , Kalla, R. , Lindstrøm, J. C. , Vatn, S. , Bergemalm, D. , Keita, Å. V. , Gomollón, F. & et al. (2022). Characterization of the circulating transcriptomic landscape in inflammatory bowel disease provides evidence for dysregulation of multiple transcription factors including NFE2, SPI1, CEBPB, and IRF2.  Journal of Crohn's & Colitis, 16 (8), 1255-1268. [BibTeX]
• Juzenas, S. , Hübenthal, M. , Lindqvist, C. M. , Kruse, R. , Steiert, T. A. , Degenhardt, F. , Schulte, D. , Nikolaus, S. & et al. (2022). Detailed transcriptional landscape of peripheral blood points to increased neutrophil activation in treatment-naïve inflammatory bowel disease.  Journal of Crohn's & Colitis, 16 (7), 1097-1109. [BibTeX]
• Moraes Holst, L. , Halfvarson, J. , Carlson, M. , Hedin, C. , Kruse, R. , Lindqvist, C. M. , Bergemalm, D. , Almér, S. & et al. (2022). Downregulated Mucosal Autophagy, Alpha Kinase-1 and IL-17 Signaling Pathways in Active and Quiescent Ulcerative Colitis.  Clinical and Experimental Gastroenterology, 15, 129-144. [BibTeX]
• Vatn, S. S. , Lindstrøm, J. C. , Moen, A. E. F. , Brackmann, S. , Tannæs, T. M. , Olbjørn, C. , Bergemalm, D. , Keita, Å. V. & et al. (2022). Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort.  Clinical and Experimental Gastroenterology, 15, 5-25. [BibTeX]
• Phillips, F. , Verstockt, B. , Sladek, M. , de Boer, N. , Katsanos, K. , Karmiris, K. , Albshesh, A. , Erikson, C. & et al. (2022). Orofacial Granulomatosis associated with Crohn's Disease: a multi-centre case series.  Journal of Crohn's & Colitis, 16 (3), 430-435. [BibTeX]
• Salomon, B. , Bergemalm, D. & Halfvarson, J. (2022). Prognostic Biosignatures at Ileocecal Resection: Hope or Reality?.  Journal of Crohn's & Colitis, 16 (6), 873-875. [BibTeX]
• Thunberg, J. , Björkqvist, O. , Hedin, C. R. H. , Forss, A. , Söderman, C. , Bergemalm, D. , Olén, O. , Hjortswang, H. & et al. (2022). Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register.  United European Gastroenterology journal, 10 (7), 631-639. [BibTeX]
• Eriksson, C. , Visuri, I. , Vigren, L. , Nilsson, L. , Kärnell, A. , Hjortswang, H. , Bergemalm, D. , Almer, S. & et al. (2021). Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.  Scandinavian Journal of Gastroenterology, 56 (11), 1304-1311. [BibTeX]
• Bergemalm, D. , Ramström, S. , Kardeby, C. , Hultenby, K. , Göthlin Eremo, A. , Sihlbom, C. , Bergström, J. , Palmblad, J. & et al. (2021). Platelet proteome and function in X-linked thrombocytopenia with thalassemia and in silico comparisons with gray platelet syndrome.  Haematologica, 106 (11), 2947-2959. [BibTeX]
• Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Udumyan, R. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2021). Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.  Therapeutic Advances in Gastroenterology, 14. [BibTeX]
• Kalla, R. , Adams, A. T. , Bergemalm, D. , Vatn, S. , Kennedy, N. A. , Ricanek, P. , Lindstrom, J. , Ocklind, A. & et al. (2021). Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.  Journal of Crohn's & Colitis, 15 (5), 699-708. [BibTeX]
• Bergemalm, D. , Andersson, E. , Hultdin, J. , Eriksson, C. , Rush, S. T. , Kalla, R. , Adams, A. T. , Keita, Å. V. & et al. (2021). Systemic Inflammation in Preclinical Ulcerative Colitis.  Gastroenterology, 161 (5), 1526-1539.e9. [BibTeX]
• Vatn, S. , Carstens, A. , Kristoffersen, A. B. , Bergemalm, D. , Casén, C. , Moen, A. E. F. , Tannaes, T. M. , Lindstrøm, J. & et al. (2020). Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character).  Scandinavian Journal of Gastroenterology, 55 (10), 1146-1156. [BibTeX]
• Burisch, J. , Bergemalm, D. , Halfvarson, J. & Munkholm, P. (2020). The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study.  United European Gastroenterology journal, 8 (8), 949-960. [BibTeX]
• Kalla, R. , Adams, A. T. , Ventham, N. T. , Kennedy, N. A. , White, R. , Clarke, C. , Ivens, A. , Bergemalm, D. & et al. (2020). Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in inflammatory bowel disease.  Journal of Crohn's & Colitis, 14 (12), 1724-1733. [BibTeX]
• Zammit, S. C. , Ellul, P. , Girardin, G. , Valpiani, D. , Nielsen, K. R. , Olsen, J. , Goldis, A. , Lazar, D. & et al. (2018). Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study.  European Journal of Gastroenterology and Hepathology, 30 (11), 1297-1303. [BibTeX]
• Bergemalm, D. , Kruse, R. , Sapnara, M. , Halfvarson, J. & Hultgren Hörnquist, E. (2017). Elevated fecal peptidase D at onset of colitis in Galphai2(-/-) mice, a mouse model of IBD.  PLOS ONE, 12 (3). [BibTeX]
• Adams, A. , Kalla, R. , Vatn, S. , Bonfiglio, F. , Nimmo, E. , Kennedy, N. , Ventham, N. , Vatn, M. & et al. (2017). Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease - IBD Character.  Journal of Crohn's & Colitis, 11 (Suppl. 1), S108-S108. [BibTeX]
• Eriksson, C. , Marsal, J. , Bergemalm, D. , Vigren, L. , Björk, J. , Eberhardson, M. , Karling, P. , Söderman, C. & et al. (2017). Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).  Scandinavian Journal of Gastroenterology, 52 (6-7), 722-729. [BibTeX]
• Ricanek, P. , Rahul, K. , Ber, Y. , Vatn, S. , Finnby, L. , Lindahl, T. , Bergemalm, D. , Carstens, A. & et al. (2017). Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease.  Journal of Crohn's & Colitis, 11 (Suppl. 1), S483-S484. [BibTeX]
• Kalla, R. , Adams, A. , Vatn, S. , Bergemalm, D. , Ricanek, P. , Lindström, J. , Ocklind, A. , Nordberg, N. & et al. (2017). Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study.  Journal of Crohn's & Colitis, 11 (Suppl. 1), S13-S13. [BibTeX]
• Andersson, E. , Bergemalm, D. , Kruse, R. , Neumann, G. , D'Amato, M. , Repsilber, D. & Halfvarson, J. (2017). Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles.  PLOS ONE, 12 (10). [BibTeX]

Conference papers

• Grännö, O. , Salomon, B. , Lindqvist, C. M. , Hedin, C. R. H. , Carlson, M. , Dannenberg, K. , Andersson, E. , Söderholm, J. D. & et al. (2024). Preclinical protein signatures in blood predict Crohn's disease and Ulcerative colitis several years before the diagnosis. In:  Journal of Crohn's & Colitis. Paper presented at 9th Congress of ECCO, Stockholm, Sweden, February 21-24, 2024. (pp. I660-I661). Oxford University Press. [BibTeX]
• Salomon, B. , Carlson, M. , Bergemalm, D. , Hedin, C. R. H. , Söderholm, J. D. , Keita, Å. V. , Carsten, A. , Grip, O. & et al. (2024). Prognostic potential of mucosal proteins in Ulcerative Colitis. In:  Journal of Crohn's & Colitis. Paper presented at 16th Congress of ECCO - European Crohn’s and Colitis Organisation (ECCO'21), (Virtual congress), July 2-3, 8-10, 2021. (pp. I544-I545). Oxford University Press. [BibTeX]
• Bazov, I. , Kruse, R. , Bergemalm, D. , Eriksson, C. , Hedin, C. R. , Carlson, M. , van Nieuwenhoven, M. , Keita, Å. V. & et al. (2023). A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts. In:  Journal of Crohn's & Colitis. Paper presented at 18th Congress of ECCO Copenhagen, Denmark, March 1-4, 2023. (pp. I314-I315). Oxford University Press. [BibTeX]
• Mahajna, H. , Verstockt, B. , Bergemalm, D. , Castiglione, F. , Rodriguez-Moranta, F. , Savarino, E. V. , Hoentjen, F. , Bessissow, T. & et al. (2022). Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series. In:  Journal of Crohn's & Colitis. Paper presented at 17th Congress of ECCO Virtual, February 16-19, 2022. (pp. I561-I561). Oxford University Press. [BibTeX]
• Wong, S. Y. , Helmus, D. , Marlow, L. , Pazos, V. M. , Brann, S. , Wellens, J. , Kedia, S. , Mak, J. W. Y. & et al. (2022). Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium. In:  Journal of Crohn's & Colitis. Paper presented at 17th Congress of ECCO Virtual, February 16-19, 2022. (pp. I357-I358). Oxford University Press. [BibTeX]
• Kalla, R. , Adams, A. , Nowak, J. , Bergemalm, D. , Vatn, S. , Ventham, N. , Kennedy, N. , Ricanek, P. & et al. (2021). EPIGENETIC ALTERATIONS IN IBD: DEFINING GEOGRAPHICAL, GENETIC, AND IMMUNEIN-FLAMMATORY INFLUENCES ON THE CIRCULATING METHYLOME. In:  Gut. Paper presented at BSG 2021 Annual Meeting Online, November 8-12, 2021. (pp. A5-A5). BMJ Publishing Group Ltd. [BibTeX]
• Phillips, F. , Verstockt, B. , Sladek, M. , de Boer, N. , Katsanos, K. , Karmiris, K. , Albshesh, A. , Eriksson, C. & et al. (2020). Orofacial granulomatosis in Crohn's disease: an ECCO CONFER multi-centre case series. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Udumyan, R. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2020). Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Bergemalm, D. , Andersson, E. , Karling, P. , Eriksson, C. , Repsilber, D. , Hultdin, J. , Halfvarson, J. & IBD Character Consortium, . (2019). Markers of systemic inflammation in preclinical ulcerative colitis. In:  United European Gastroenterology journal. Sage Publications. [BibTeX]
• Eriksson, C. , Bergemalm, D. , Vigren, L. , Nilsson, L. , Visuri, I. , Hjortswang, H. , Udumyan, R. , Almer, S. & et al. (2018). Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG. In:  Journal of Crohn's & Colitis. Paper presented at 13th Congress of ECCO – European Crohn’s and Colitis Organisation, Vienna, Austria, February 14-17, 2018. (pp. S409-S410). Oxford University Press. [BibTeX]
• Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Karlen, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD). In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Karlen, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC). In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Vatn, S. , Karlsson, M. C. , Carstens, A. , Detlie, T. E. , Ricanek, P. , Bergemalm, D. , Lindquist, C. M. , Jahnsen, J. & et al. (2018). Faecal microbiota in newly diagnosed Crohn's disease and its relation to treatment escalation. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Vatn, S. , Karlsson, M. C. , Carstens, A. , Detlie, T. E. , Ricanek, P. , Lindquist, C. M. , Bergemalm, D. , Jahnsen, J. & et al. (2018). Faecal microbiota in treatment-naive ulcerative colitis and its relation to treatment escalation. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Kalla, R. , Adams, A. T. , Vatn, S. , Bonfiglio, F. , Nimmo, E. R. , Kennedy, N. A. , Ventham, N. , Vatn, M. H. & et al. (2017). Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – ibd character. In:  Gut. Paper presented at Annual General Meeting of the British-Society-of-Gastroenterology (BSG), Manchester, England, June 19-22, 2017. (pp. A24-A25). BMJ Publishing Group Ltd. [BibTeX]
• Kalla, R. , Adams, A. T. , Vatn, S. , Bergemalm, D. , Ricanek, P. , Lindstrom, J. C. , Ocklind, A. , Nordberg, N. & et al. (2017). Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: ibd character study. In:  Gut. Paper presented at Annual General Meeting of the British-Society-of-Gastroenterology (BSG), Manchester, England, June 19-22, 2017,. (pp. A202-A203). BMJ Publishing Group Ltd. [BibTeX]
• Andersson, E. , Bergemalm, D. , Kruse, R. , D'Amato, M. , Repsilber, D. & Halfvarson, J. (2016). Inflammatory biomarkers in serum discriminate Crohn's disease and ulcerative colitis from healthy controls. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Kalla, R. , Ocklind, A. , Petren, C. , Nordberg, N. , Kennedy, N. , Ventham, N. , Pettersson, E. , Bergemalm, D. & et al. (2016). Proximity extension assay immunoassay technology identifies novel serum biomarkers that can diagnose and classify inflammatory bowel diseases: IBD Character Consortium. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
• Kalla, R. , Kennedy, N. , Hjelm, F. , Modig, E. , Sundell, M. , Andreassen, B. , Bergemalm, D. , Ricanek, P. & et al. (2015). Proximity Extension Assay technology identifies novel serum biomarkers for predicting Inflammatory Bowel Disease: IBD Character Consortium. In:  Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]

Manuscripts

• Carstens, A. , Björkqvist, O. , Lindqvist, C. M. , Rangel, I. , Repsilber, D. , Eriksson, C. , Bergemalm, D. , Bresso, F. & et al. Gut microbiota associated with treatment outcome to biological treatment in inflammatory bowel disease. [BibTeX]
• Koskela von Sydow, A. , Janbaz, C. , Bergemalm, D. & Ivarsson, M. IL-1α counteracts TGF-β regulated protein expression in human dermal fibroblasts. [BibTeX]
• Fart, F. , Amcoff, K. , Bergemalm, D. , Andersson, E. , Kalla, R. , Satsangi, J. , Lindqvist, C. M. , Halfvarson, J. & et al. Loss of tolerance to microbial antigens in preclinical Crohn’s disease differs with age at diagnosis : A twin study. [BibTeX]